Introduction: Notch receptor family dysregulation can be tumor promoting or suppressing depending on cellular context. Our studies shed light on the mechanistic differences that are responsible for NOTCH1's opposing roles in lung adenocarcinoma and lung squamous cell carcinoma.
Introduction
Notch signaling plays a fundamental role during embryonic development and adult tissue homeostasis. 1 In cancer, abnormal regulation of Notch signaling can occur through multiple types of genomic alterations and changes to various regulatory pathways. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] The Notch pathway is involved in most of the hallmarks of cancer and its role can vary widely depending on cancer subtype. 11 NOTCH1, in particular, has cell autonomous and non-autonomous roles resulting in oncogenesis or tumor suppression in different contexts, cancer subtypes, and specific gene backgrounds. [3] [4] [5] [6] [7] [8] [9] [10] [11] Unfortunately, the *Corresponding author.
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mechanistic details of these various roles are not well understood. 11 The evidence that NOTCH1 can be an oncogene or a tumor suppressor comes from mutational analysis of tumors and limited in vitro studies. More than 50% of human T-cell acute lymphoblastic leukemia have activating mutations in NOTCH1. 12, 13 In vitro and in vivo studies have shown that NOTCH1 acts as an oncogene in lung adenocarcinoma (AD) where it plays a critical role in invasion, metastasis, and malignant transformation. [3] [4] [5] 14 In contrast, a tumor suppressive role of Notch has been claimed across different squamous cell carcinoma (SCC) tumors based on the loss of function mutations commonly found in cutaneous SCC. 15 Mutational analysis has not given us the full picture of how Notch signaling functions in different cancer types and another approach is needed. Notch mutations have been identified in less than 10% of lung tumors, but aberrant Notch signaling has been reported in 33% of NSCLCs. 16 In the absence of mutations, the role of Notch in cancer progression can be probed by determining the phenotypic response to perturbation of Notch signaling. 11 The importance of Notch expression is reflected in the fact that NOTCH1 expression levels in nonmutated tumors have opposite prognostic effects in AD and SCC. [17] [18] [19] [20] Although a number of Notch-targeted therapies have been tried (Supplemental Table 1 ), none has resulted in significant clinical benefit in unselected patient populations. Defining the functional roles of Notch in different tumor subtypes is essential to understand its biology and to provide better therapeutic options for cancer patients. Recent papers suggest that Notch plays a key role maintaining the balance of immune cells within the tumor microenvironment. [21] [22] [23] [24] The gap in our understanding of NOTCH1's role in regulating the tumor microenvironment adds to the complexity of predicting the outcome of therapeutic modulation of NOTCH1. 10 One method of inferring gene function is coexpression analysis. Differential co-expression networks have been used to identify disease-associated genes and gene modules in solid and hematologic tumors. 25 It can be used to define tumor intrinsic and extrinsic biological processes associated with a gene of interest in a particular disease or disease subtype. 21, 23, 26 To date, no studies have examined or compared the vector of correlation coefficients between the Notch family of transcription factors and the transcriptome in an unbiased manner in human solid tumors.
Here we have identified differential co-expression networks of Notch gene expression. In our analysis, we revealed a pattern of gene co-expression with NOTCH1 in lung AD that is very different from lung SCC and identified pathways that could underlie the observed differences in Notch function. We confirmed these observed differences in vitro and in vivo. We further identified potential links associated with these differences by proteomic examination of the NOTCH1 interactome using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-tagged endogenous models. We believe that this combined bioinformatics and proteomics approach provides insights revealing possible novel mechanisms underlying the opposing roles of NOTCH1 in lung cancer.
Materials and Methods

Cell Culture
Two lung AD cell lines (A549, H358) and two lung SCC cell lines (HCC15, HCC95) were used. Cells were grown in standard culture medium under standard conditions at 37 C in a humidified atmosphere, 5% CO 2 . Additional details about cell culture including authentication and mycoplasma testing are provided in the Supplemental Methods.
Preparation of The Cancer Genome Atlas Clinical and Transcriptional Datasets
The top 13 solid epithelial cancers ranked by estimated deaths in 2017 were identified using data from the American Cancer Society. 27 The Cancer Genome Atlas (TCGA) has 38 cancer datasets with publicly available RNAseqV2 data (http://firebrowse.org/). RNA-Seq by expectation maximization normalized data from 14 datasets that matched categories with the top 13 solid epithelial cancers (Table 1) were used. Selected tumor subtypes were confirmed by a clinical pathologist (K.S.). Additional details regarding data sets and analysis are provided in Supplemental Methods.
Data Visualization
The ClustVis tool (http://biit.cs.ut.ee/clustvis/) was used for principal component analysis (PCA) with gene scaling using the SVDimpute algorithm. Global transcriptional patterns were visualized using the heatmaply package in R3.4.0 (2017-04-21) using clustering determined by Euclidean distance with complete linkage. 28, 29 Descriptive statistics, unsupervised hierarchical clustering with distances defined by Euclidian distance and Ward's linkage, and Venn diagrams were produced in JMP-Pro 12.2.0.
Gene List Enrichment Analysis
Enrichment analysis was performed using Entrez gene identifiers. The biological relevance of the network modules used the ToppGene Suite (Division of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, http://toppgene.cchmc.org) and was performed using probability density function method, false discovery rate (FDR) p value cutoff of 0.05 and verified with DAVID and Ingenuity Pathway Analysis. [30] [31] [32] [33] Additional details, raw gene input, and results from ToppGene are provided in Supplemental Methods and Supplemental Dataset 1. Enrichment analysis of RNA-sequencing data from human xenografts samples was performed in ingenuity pathway analysis and is further described in Supplemental Methods.
Short Hairpin RNA Vectors
Short hairpin RNA (shRNA) knockdown (KD) experiments were performed using the pLKO.1-puro vector. To knockdown NOTCH1 expression we used NOTCH1 Mission shRNA's (Sigma, SHCLNG-NM_017617: TRCN0000003359,TRCN0000003362,TRCN0000350254) or nontargeting control (NTC) (Sigma,SHCO16). We refer to each NOTCH1 knockdown by the last four TRCN digits.
NOTCH1 shRNA Virus Production and Cell Line Transduction
Lentiviral particles were produced by transfecting 293FT packaging cells with packaging-psPAX2, envelope-pMD2.G, and shRNA plasmid. Experiments were begun 24 hours after infection. KD efficiency was assessed by immunoblot analysis of NOTCH1 protein expression after 72 hours. Additional details are provided in the Supplemental Methods. 
Metabolic Proliferation Assay
Cells were seeded (2500 cells/well) in a 96-well plate in culture and incubated for 72 hours under standard conditions. Assays were run using a standard alamarBlue (Thermo#DAL1100) assay protocol, using 3-hour incubation, three technical replicates, three biologic replicates, and repeated in triplicate. Error bars indicate the mean ± SEM. Immunoblots were harvested and run in parallel to verify NOTCH1 expression levels on the day metabolic readouts were assessed (72 h).
Xenografts
Female NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) mice were obtained from The Ohio State University (OSU) Target Validation Shared Resource. Six-week-old mice Table 1 (n > 50), PC1 and PC2 account for 17.7% and 14.3% of the total variance, respectively. Cancers were classified as adenocarcinoma (AD) squamous cell carcinoma (SCC) or other. Circles indicate datasets with similar patterns of NOTCH1-correlated genes that clustered together. (C) Unsupervised hierarchical clustering of genes (n ¼ 6634) correlated with NOTCH1 that are statistically significant (n ¼ 2 datasets). (D) Venn diagram of genes that were significantly different between LUAD and LUSC datasets (n ¼ 1659). The size of the Venn diagrams are proportional to the number of genes significantly correlated with NOTCH1 in LUAD (blue) or LUSC (green) datasets. Statistical significance of genes in C determined by beta-uniform mixture model FDR < 0.001 and in D by FDR < 0.002. Clustering in A determined by Euclidian distance and Wards linkage and in C determined by Euclidean distance with the complete linkage. PCA in B was generated with gene scaling using the SVDimpute algorithm in ClustVis (http://biit.cs.ut.ee/clustvis_large/). LUAD, TCGA lung adenocarcinoma dataset; LUSC, TCGA lung squamous cell carcinoma dataset; HNSCC, TCGA head and neck squamous cell carcinoma dataset; N1, NOTCH1; N2, NOTCH2; N3, NOTCH3; N4, NOTCH4; PC, principal component; TCGA, The Cancer Genome Atlas; PAAD, ancreatic adenocarcinoma; ESCA, esophageal squamous cell carcinoma; FDR, false discovery rate. See Table 1 for complete dataset names from B.
were implanted with 10 Â 10 6 cells. Four tumor models (A549, H358, HCC15, and HCC95) were used. For each tumor model, four mice were implanted using paired NTC and NOTCH1 KD#0254 constructs on bilateral flanks. All tumors harvested were assessed by ex vivo analysis. Studies were blinded to group assignment. Additional details are provided in the Supplemental Methods.
Immunohistochemistry Staining and Analysis
Formalin-fixed paraffin-embedded xenograft tumor sections from paired NTC and NOTCH1 KD mice were stained by OSU Solid Tumor Shared Resource using the Leica Bond RX system. Immunohistochemistry (IHC) staining was performed for anti-CD31 (Abcam#ab28364,1:50) and pHH3 (CST#9701,1:200). Biological replicates from in vivo studies were used; for each mouse, 1 NTC and KD xenograft tumor sections were stained (4 cell lines, 4 mice/cell line). Additional details regarding sample analysis are provided in the Supplemental Methods.
RNA Sequencing
RNA from flash-frozen tissue from paired NTC and NOTCH1 KD xenograft tumor sections lung AD model (A549) and in the lung SCC model (HCC15) were sequenced. Eight tumors were sequenced (2 cell lines, 2 mice/cell line). Additional details regarding data generation and analysis are provided in the Supplemental Methods. 
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Immunoblots
Cell lysates were harvested while cells were in exponential growth phase or from flash-frozen tissue in lysis buffer, homogenized, and run on precast gels (BioRad#4561083). Standard LiCor techniques were used for antibody staining using primary antibodies. Additional details are provided in the Supplemental Methods.
Affinity Purification-Mass Spectrometry/Mass Spectrometry
Descriptions of molecular cloning work, CRISPR-Cas9 gene editing, DNA constructs, stable and transient transductions, co-immunoprecipitation validations, and the proteomic procedure and analyses for the discovery dataset are described in the Supplemental Methods and Supplemental Dataset 2. Briefly, the protocol for mass spectrometry (MS)-based investigation of protein-protein interactions were based on in-solution (single) affinity purification followed by ultraperformance liquid chromatography-tandem mass spectrometry. For each of the 4 cell line samples (A549, H358, HCC15, and HCC95) two controls and three biological replicates were analyzed. Samples were prepared at OSU and analyzed at the University of Michigan (Proteomics Resource Facility, Department of Pathology).
Statistics
Detailed methods for statistical evaluation regarding all components of the described studies are contained in the Supplemental Methods.
Study Approval
All animal studies were performed in accordance with the protocols approved by OSU Institutional Animal Care and Use Committee (IACUC, Protocol#2014A00000116) and in accordance with the accepted standard of humane animal care, American Association for Laboratory Animal Care Institutional Guidelines.
Results and Discussion
Unique Role of NOTCH1 Signaling in Solid Epithelial Cancers
The Notch signaling pathway, with multiple receptors and ligands, is very complex and plays important roles in almost every aspect of cancer. 11 As such, Notch is a potential target for cancer therapy. 34 However, Notch can be oncogenic or tumor suppressive depending on the cancer type. 2, 11 Unfortunately, the individual role of each Notch receptor or ligand is cancer-specific and the behavior of each Notch family member in different cancer types is unclear.
To gain a better understanding of how Notch works in various cancers, we analyzed TCGA transcriptional datasets associated with solid epithelial cancers with the highest mortality rates in the United States (Table 1) . A correlation matrix was built on pairwise correlations between the expression of each of the four Notch receptors or five ligands and all other genes for each dataset. Two-way hierarchical clustering with Euclidian distance and Wards linkage rule was performed to help detect the existence of multivariate structures (Supplemental Fig. 1) . Patterns of gene co-expression with NOTCH2, 3, and 4 receptors were consistent across tumor types suggesting a conserved function. However, the NOTCH1 receptor showed a very different clustering pattern between tumors (Fig. 1A and Supplemental Fig. 1 ). For example, as shown in Figure 1A , both SCC datasets (lung SCC [LUSC] and head and neck SCC [HNSCC]) clustered together whereas NOTCH1 in the lung adenocarcinoma (LUAD) dataset clustered at the opposite end of the dendrogram (farthest distance away) indicating that different sets of genes are co-expressed with NOTCH1 in this subtype.
Global differences or similarities of NOTCH1 coexpression in solid epithelial cancers was assessed by PCA and revealed a group of cancers that clustered (circles, Tables 4 and 5 . GTPase, guanosine triphosphate; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma.
Fig. 1B).
A pooled statistic was calculated to identify genes associated with these clusters (circles). Enrichment analysis in ToppGene on genes significantly correlated (FDR 1.0%) within these clusters indicated gene ontology (GO) biological processes involved in RNA processing, cell cycle, and cellular macromolecule localization (Supplemental Table 2 ). Our PCA results also show that histology alone may not be sufficient. For example, colorectal cancer is classified histologically as an AD, but in our analysis the colon and rectal datasets clustered near the SCCs. The recent failure of a NOTCH1 inhibitor in a colorectal phase1b clinical trial are consistent with our in silico predictions and suggest that NOTCH1 may not act as an oncogene in unselected colorectal carcinomas. 35 As datasets get larger, functionally important NOTCH1 subgroups within each histologic type might be better defined.
Co-Expression Analysis as a Valuable Tool for Identifying Novel NOTCH1 Pathway Susceptibilities in Lung Cancer
NSCLC is an example of a tumor type that shows both AD and SCC differentiation. The clinical characteristics of patients in the LUAD and LUSC datasets were similar (Supplemental Table 3 ). The TCGA esophageal and cervical datasets were used for validation of our methods because they represent both AD and SCC histology. The HNSCC dataset was also evaluated as another upper aerodigestive tumor type with similar etiology to LUSC. Statistical analyses were performed to identify genes that were significantly correlated with NOTCH1. To correct for multiple hypotheses, we used the betauniform mixture model to estimate the p value distribution and Benjamin-Hochberg method controlling FDR at alpha ¼ 0.001. [36] [37] [38] A high percentage, 44.5% (n ¼ 6634) of genes were significantly correlated with NOTCH1 in either the LUAD or LUSC dataset. A heatmap of genes with Pearson correlation coefficients that reached significance is shown in Figure 1C . Analysis of NOTCH1 co-expressed genes (n ¼ 6634) with the validation datasets recapitulated distinct clustering of AD or SCC cancer subtypes (Supplemental Figs. 2A and B) . We performed a Fisher z-transformation to rescale the correlation coefficients to a standard normal assuming the null hypothesis that no correlation is true. We used Fisher z-scores to identify genes differentially correlated 
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with NOTCH1 in the LUAD or LUSC dataset (FDR, alpha ¼ 0.002). The number of genes differentially correlated within each dataset is depicted in the Venn diagram (Fig. 1D) , shown in Supplemental Figure 2C with the validation datasets and listed in Supplemental Dataset 1. The top 10 genes that were uniquely associated with either dataset (Table 2) show differences in NOTCH1 co-expression between the datasets (Supplemental Figs. 3 and 4) .
Functional enrichment analyses provided insights on the biological pathways associated with differential biomolecular networks (co-expressed genes) (n ¼ 1659). In LUAD, NOTCH1 co-expression was distinctly enriched for pathways associated with angiogenesis and vascular development, immune system, and Rho guanosine triphosphatase activity (Table 3 , Supplemental Fig. 5 , and Supplemental Table 4 ). For example, higher expression of NOTCH1 was positively correlated with the expression of the vascular pathway genes (MMRN2, VWF, and NOTCH4) in the LUAD dataset (pink, Supplemental Fig. 6A ). In contrast, there was no clear correlation between these vascular genes and NOTCH1 in the LUSC dataset (teal). Likewise, higher expression of NOTCH1 was positively correlated with the expression of immune markers including innate immune cells, macrophages, dendritic cells and immune stem cells in the LUAD dataset (pink) but not LUSC dataset (teal, Supplemental Fig. 6B ). In the LUAD dataset, we observed a positive correlation between the expression of myeloid/macrophage biology genes as exemplified by CD93. 39, 40 This is consistent with the literature that suggests Notch signaling plays a role in myeloid/macrophage biology where CD93 plays a key role in differentiation of monocytes to macrophages. 39 In addition, chemokines such as CCL14 and chemokine receptors involved in the innate immune system were related to NOTCH1 expression in LUAD (data not shown).
In lung SCC, NOTCH1 co-expression was uniquely enriched for genes related to cell cycle, macromolecular complex binding, and chromosome pathways (Table 3 , Supplemental Fig. 7 , and Supplemental Table 5 ). For example, the expression levels of mitotic genes (e.g., BUB1B, ASPM, and TOP2A) were positively correlated in the LUSC dataset, but negatively correlated in the LUAD dataset (Supplemental Fig. 6C ). Enrichment analysis on genes correlated with the clustered datasets from multiple tumor types (Fig. 1B) , which included all of the SCC datasets, and also indicated that cell cycle pathways were associated with NOTCH1 co-expression (Supplemental Table 2 ).
Finally, lineage-specific biomarkers for LUAD and LUSC were not differentially correlated with NOTCH1. The LUAD biomarker, cytokeratin 7 (KRT7) and LUSC biomarker, tumor protein p63 (TP63), showed the expected differences in expression, but not in correlations with NOTCH1 in the LUAD and LUSC datasets. Thus, the differences in correlations observed were not just markers of specific lineages (Supplemental Fig. 8 ).
NOTCH1 Shows Opposite Functional Effects in LUAD and LUSC In Vitro and In Vivo
The role of Notch perturbation in lung cancer is unclear. Wael et al. 41 showed that NOTCH1 has a tumor suppressive role in the LUAD (A549) model and no effect in the LUSC (H2170) model. In contrast, many other studies have shown an oncogenic role for NOTCH1 in LUAD but have not experimentally shown the role of NOTCH1 in LUSC. [3] [4] [5] 14 There have been no direct comparisons between LUAD and LUSC in well-controlled experiments in vitro and in vivo.
We knocked down NOTCH1 in LUAD (A549, H358) and LUSC (HCC15, HCC95) cell lines with three different lentiviral shRNA constructs. All four cell lines endogenously express NOTCH1 (Supplemental Fig. 9 ) and do not have Notch mutations. In the LUAD cell lines, all three lentiviral shRNA constructs resulted in decreased NOTCH1 expression and reduced cell proliferation relative to NTC ( Figs. 2A and B) . In contrast, NOTCH1 KD resulted in decreased NOTCH1 expression but increased cell proliferation in LUSC cell lines. These results show an opposing phenotypic response to NOTCH1 KD in NSCLC. Paired immunoblots showed that that the strength of the phenotype correlated with the degree of knockdown in most cell lines (Fig. 2B) . KD of NOTCH1 in vivo supported a pro-growth role in LUAD and tumor suppressive role in LUSC. Cell lines infected with either NOTCH1 KD construct (shRNA#0254) or NTC control were implanted in bilateral flanks as subcutaneous xenografts in NSG mice. KD of NOTCH1 in the LUAD cell lines (A549, H358) resulted in tumors with significantly reduced tumor volume relative to NTC, supporting a pro-growth role of NOTCH1 in AD (Figs. 3A and B) . In contrast, KD of NOTCH1 in LUSC models resulted in significant increase in tumor growth, supporting a tumor suppressive role of NOTCH1 in SCC (Figs. 3C and D) . The relative levels of NOTCH1 knockdown at the beginning and end of our study are shown in Supplemental Figures 10 and 11 .
Unlike prior studies that have extrapolated a tumor suppressor function for NOTCH1 in LUSC from the existence of loss of function mutations, these experiments show the pro-growth and tumor suppressive role of NOTCH1 in vitro and in vivo in controlled lung models.
42
NOTCH1 Has Different Effects on Mitotic, Vascular, and Immune Pathways in LUAD and LUSC
To explore how NOTCH1 KD experimentally correlates with changes in mitotic, vasculature, and immune process predicted by our in silico studies, we performed IHC staining and RNA-sequencing on the human LUAD and LUSC xenograft tumors collected at the end of the study. For IHC analysis, formalin-fixed paraffinembedded sections from all tumors were stained for phosphohistone H3 (pHH3; mitotic marker) and cluster of differentiation 31 (CD31; vascular marker) (Figs. 3E and F). Flash-frozen tumor xenografts were evaluated for changes in human and mouse mRNA following NOTCH1 KD in two of the LUAD model (A549) and LUSC model (HCC15) xenografts.
Gene enrichment analysis revealed that genes distinctly co-expressed with NOTCH1 in the LUSC dataset were enriched in pathways involved in cell cycle, specifically mitosis, macromolecular complex binding, and chromosomal organization and binding (Table 3,  Supplemental Table 5 ). Experimentally, we observed that NOTCH1 inhibition had different effects on cell cycle pathways in LUAD and LUSC. NOTCH1 KD corresponded with a significant increase in pHH3 expression in tumors generated from the LUSC but no significant change in pHH3 expression in the LUAD cell lines (Fig. 3G) as predicted by our in silico analysis. Furthermore, pathway analysis of the RNA sequencing data supported our IHC results and predicted activation of the G2 phase of cell cycle progression in the LUSC model (HCC15) but decreased function in the LUAD model (A549) with NOTCH1 KD (Supplemental Table 6 ). Together, our in silico, in vitro, in vivo, IHC, and RNA sequencing studies in LUSC suggest that antimitotic therapies as single agents or in combination with NOTCH1 agonists may be useful in the treatment LUSC patients. Our hypothesis is supported by the findings of Ye et al. 43 who reported that a specific inhibitor of CDC7 (LY3177833), which plays a role in cell cycle, centromere cohesion, and chromosome segregation, resulted in tumor stasis or regression in the majority of LUSC cancer patientderived tumor models. 43 The comparable co-expression patterns we observed in other types of SCC (Fig. 1A) suggest that this hypothesis may be generalizable to additional SCC cancers. Future studies may bring additional insights to these intriguing observations. Vascular pathways were distinctly associated with the LUAD dataset but not in the LUSC dataset (Table 3 , Supplemental Fig. 6A ). In LUAD tumors, NOTCH1 KD resulted in a significant increase in CD31 expression, but was unchanged or decreased in LUSC tumors (Fig. 3H) . Although it is counterintuitive that we should see increased CD31 staining because that might imply a progrowth phenotype, other studies have observed an increase of endothelial proliferation following NOTCH1 inhibition and the production of nonfunctional vessels resulting in vascular leakage and dysfunction. 44 Studies have also shown that the expression of NOTCH1 and VEGFA in LUAD have a significant negative prognostic impact in the LUAD cohort.
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NOTCH1 has been implicated in the regulation of the innate immune system and involvement of myeloid/ macrophage biology. 11, 45 In our study, NOTCH1 inhibition had opposing effects on the transcription levels of mouse immune and inflammatory response genes. Our RNA sequencing pathway analysis of in vivo NOTCH1 KD tumors in LUAD (A549) predicted an increase in the recruitment of the innate immune and inflammatory system components and a decrease in LUSC (HCC15) (Supplemental Table 7 ).
Other studies have proposed that DLL1 ligand treatment results in increased Notch activity and may be beneficial by enhancing T-cell infiltration in tumors. 46 Our studies were performed using human cell lines with NOTCH1 KD that were implanted in NSG mice. These animals lack T and B cells, but the mouse innate immune system is at least partially intact. Recent studies have shown that NSG mouse monocytes and granulocytes exert a host versus graft response that can lead to rejection of human tissue. 47, 48 Although preliminary, our RNA sequencing results support our in silico findings. Additional studies are required to validate the association of NOTCH1 function with cell cycle, vascular, and immune pathways in subsets of human solid tumors. New ex vivo autologous models are in development that may also enable the investigation of primary human tumors in the presence of human microenvironment components. 49 
NOTCH1 Has Distinct Protein Interactions in LUAD and LUSC
Comparison of Notch interacting proteins in LUAD and LUSC could yield clues about the environment in which NOTCH1 exerts its opposing effects. Prior studies have relied on artificial overexpression systems potentially resulting in unintended and/or nonspecific interactions due to higher, non-physiological levels of NOTCH1 protein. We inserted the FLAG epitope sequence into the last coding exon of the NOTCH1 gene using CRISPR Cas-9 gene editing to prevent these potential issues (Fig. 4A) . Using affinity purification-MS/ MS at endogenous expression levels of NOTCH1, we showed both novel as well as known (e.g., RBPJ, MAML) NOTCH1 protein interactions.
Our comparison of interacting proteins identified 15 proteins that uniquely interacted with NOTCH1 in LUAD cell lines (A549, H358) and 10 proteins that only interacted with NOTCH1 in LUSC cell lines (HCC15, HCC95) (Supplemental Table 8 , Fig. 4B ). A number of mitochondrial proteins were identified to interact with NOTCH1 (Supplemental Table 9 ). We validated the potential for NOTCH1 to interact with four of the novel interacting proteins: SDHA, SDHB, IDH2, and AATF. NOTCH1 interactions were specific; we detected NOTCH1 interaction with the positive control RBPJ-MYC or RBPJ-FLAG and NOTCH1-ICD V5 (Figs. 4C and D) , but not in our negative control experiment with GFP-FLAG (Fig. 4E) . Anti-V5 coimmunoprecipitation experiments showed that SDHA-MYC, SDHB-FLAG, IDH2-MYC, and AATF-MYC interacted with NOTCH1-ICD V5 but not vector control (Figs. 4F-I) , signifying that the interactions were dependent on the presence of the bait (NOTCH1-ICD). Taken together these results support our proteomics findings.
These results suggest that NOTCH1 may engage in context dependent protein interactions. Three mitochondrial proteins SDHB, IDH2, and MRPS22 that we identified interacting in LUAD but not LUSC models are known to have key roles in cancer including effects on metabolism, HIF1A stabilization, and impairment of DNA methylation. [50] [51] [52] IDH2 is a very interesting link given that the genetic variant rs11540478 is a risk factor for lung cancer. 53 Additionally, high serum levels of IDH2 correlate with poor survival in NSCLC. 54 Additional experiments are needed to further validate how and if these interactions contribute to the opposing phenotypes of NOTCH1 in NSCLC.
Conclusions
The current study provides insights into the molecular differences that may underlie the diverse effects of NOTCH1 in different lung cancer subtypes. Our findings extend the results of prior loss of function and mutation studies and importantly show that NOTCH1 has a tumor suppressor role in LUSC that is independent of mutations. Specific downstream pathway targeting with angiogenesis inhibitors, cell cycle inhibitors, and immune modulators may be particularly effective in the NOTCH1 subsets defined here. Together our findings shed new light on the complex Notch signaling pathway, and provide leads for potentially important functional subgroups of tumors and novel differential interacting proteins for future molecular studies.
